Efficacy and Toxicity of Classical Immunosuppressants, Retinoids and Biologics in Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a chronic inflammatory disorder of the apocrine glands characterized by recurrent episodes. Although several therapies exist, none is completely curative. Several immunosuppressives have been studied with encouraging results and targeted approaches. In this review, we highlight the various immunosuppressives used in this condition along with their salient features to enable physicians to choose the correct therapy for their patients. The search of the peer-reviewed literature included clinical trials, scientific reviews, case series, case reports, and guidelines. The literature was identified from electronic databases (MEDLINE and PubMed) through November 2021; additional articles were included from the references of the identified articles.

[1]  G. Jemec,et al.  Medical and Surgical Management of Hidradenitis Suppurativa: A Review of International Treatment Guidelines and Implementation in General Dermatology Practice , 2020, Dermatology.

[2]  E. Giamarellos‐Bourboulis,et al.  Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa , 2020, Expert opinion on drug safety.

[3]  A. Kimball,et al.  Methotrexate shows benefit in a subset of patients with severe hidradenitis suppurativa , 2020, International journal of women's dermatology.

[4]  T. Aune,et al.  Methotrexate and its mechanisms of action in inflammatory arthritis , 2020, Nature Reviews Rheumatology.

[5]  Therezia Bokor-Billmann,et al.  The Role of the Cutaneous Microbiome in Hidradenitis Suppurativa—Light at the End of the Microbiological Tunnel , 2020, International journal of molecular sciences.

[6]  Dapsone , 2020, Reactions Weekly.

[7]  A. Tobin,et al.  Could isotretinoin flare hidradenitis suppurativa? A case series , 2019, Clinical and experimental dermatology.

[8]  C. Harview,et al.  Isotretinoin in the treatment of hidradenitis suppurativa: a retrospective study , 2019, The Journal of dermatological treatment.

[9]  H. H. Oon,et al.  Systematic review of immunomodulatory therapies for hidradenitis suppurativa , 2019, Biologics : targets & therapy.

[10]  F. Bekara,et al.  Hidradenitis Suppurativa: A Systematic Review and Meta-analysis of Therapeutic Interventions. , 2019, Indian journal of dermatology, venereology and leprology.

[11]  G. Duarte,et al.  Consensus on the treatment of hidradenitis suppurativa - Brazilian Society of Dermatology* , 2019, Anais brasileiros de dermatologia.

[12]  A. Nassif,et al.  Are Bacteria Infectious Pathogens in Hidradenitis Suppurativa? Debate at the Symposium for Hidradenitis Suppurativa Advances Meeting, November 2017. , 2019, The Journal of investigative dermatology.

[13]  I. Walecka,et al.  Hidradenitis suppurativa – known and unknown disease , 2018, Reumatologia.

[14]  D. Sotiriadis,et al.  Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data , 2018, Dermatology reports.

[15]  A. Navarini,et al.  Swiss Practice Recommendations for the Management of Hidradenitis Suppurativa/Acne Inversa , 2017, Dermatology.

[16]  J. Boer.  Are There Indications for Isotretinoin Treatment of Hidradenitis Suppurativa? , 2017, Dermatology.

[17]  S. Walsh,et al.  Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa. , 2016, Journal of the American Academy of Dermatology.

[18]  A. Gottlieb,et al.  Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study. , 2016, Journal of drugs in dermatology : JDD.

[19]  Esther S. Kim,et al.  Adalimumab: A Review in Hidradenitis Suppurativa , 2016, American Journal of Clinical Dermatology.

[20]  A. Gottlieb,et al.  Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. , 2016, The New England journal of medicine.

[21]  G. Jemec,et al.  Cyclosporine treatment of severe Hidradenitis suppurativa – A case series , 2016, The Journal of dermatological treatment.

[22]  E. Prens,et al.  Azathioprine lacks efficacy in hidradenitis suppurativa: a retrospective study of nine patients , 2016, The British journal of dermatology.

[23]  J. Lapins,et al.  European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[24]  J. Jais,et al.  Bacterial Pathogens Associated with Hidradenitis Suppurativa, France , 2014, Emerging infectious diseases.

[25]  J. Szepietowski,et al.  Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients , 2014, The British journal of dermatology.

[26]  N. Scheinfeld.  Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients. , 2013, Dermatology online journal.

[27]  M. Jonkman,et al.  Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review , 2013, The British journal of dermatology.

[28]  G. Jemec,et al.  Dapsone Therapy for Hidradenitis Suppurativa: A Series of 24 Patients , 2011, Dermatology.

[29]  J. Boer,et al.  Long‐term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? , 2011, The British journal of dermatology.

[30]  F. Kerdel,et al.  Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. , 2010, Journal of the American Academy of Dermatology.

[31]  A. Layton.  The use of isotretinoin in acne , 2009, Dermato-endocrinology.

[32]  J. Revuz,et al.  Absence of Efficacy of Oral Isotretinoin in Hidradenitis Suppurativa: A Retrospective Study Based on Patients’ Outcome Assessment , 2008, Dermatology.

[33]  M. Kaur,et al.  Hidradenitis suppurativa treated with dapsone: A case series of five patients , 2006, The Journal of dermatological treatment.

[34]  G. Koretzky,et al.  Azathioprine: old drug, new actions. , 2003, The Journal of clinical investigation.

[35]  G. Jemec.  Methotrexate is of limited value in the treatment of hidradenitis suppurativa , 2002, Clinical and experimental dermatology.

[36]  P. Nos,et al.  Hidradenitis Suppurativa and Crohn's Disease: Response to Treatment with Infliximab , 2001, Inflammatory bowel diseases.

[37]  M. Stiller,et al.  Dapsone and sulfones in dermatology: overview and update. , 2001, Journal of the American Academy of Dermatology.

[38]  S. Matsuda,et al.  Mechanisms of action of cyclosporine. , 2000, Immunopharmacology.

[39]  G. Jemec.  Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. , 1999, Journal of the American Academy of Dermatology.

[40]  K. Radcliffe,et al.  Hidradenitis suppurativa. , 1991, Genitourinary medicine.

[41]  D. Hogan,et al.  Successful treatment of hidradenitis suppurativa with acitretin. , 1988, Journal of the American Academy of Dermatology.

[42]  G. Cains,et al.  Hidradenitis suppurativa - Management, comorbidities and monitoring. , 2017, Australian family physician.

[43]  J. Ingram.  The Genetics of Hidradenitis Suppurativa. , 2016, Dermatologic clinics.

[44]  H. C. Ring,et al.  The Microbiology of Hidradenitis Suppurativa. , 2016, Dermatologic clinics.

[45]  B. Strober,et al.  SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate. , 2011, Bulletin of the NYU hospital for joint diseases.